Abstract
An obstacle confronting gene therapy in stem cells is transcriptional silencing of the vector. Here, we discuss recent data indicating that oncoretrovirus and lentivirus vectors are silenced by multiple epigenetic pathways that result in DNA methylation and histone modifications. Both vector types can be variegated in stem cells and expression is often extinguished during differentiation. We propose a novel model of retrovirus silencing in which epigenetic pathways compete to recruit histone deacetylases, de novo methyltransferases, histone H1 and MeCP2 to the provirus. These chromatin modifications may act in concert with heterochromatin at or near the integration site to establish silencing or variegation respectively. Retrovirus vector designs for stem cells should delete virus silencer elements, incorporate strong positive regulatory elements and insulators, and avoid non-mammalian reporter genes. In addition, cancer stem cells that continually repopulate a growing tumour may share silencing pathways with normal stem cells. Ultimately, optimized vector designs may prove to be valuable tools for gene therapy of both normal and cancer stem cells.
Keywords: stem cells, heterochromatin, non-mammalian reporter genes
Current Gene Therapy
Title: Retrovirus Silencing and Vector Design: Relevance to Normal and Cancer Stem Cells?
Volume: 5 Issue: 4
Author(s): James Ellis and Shuyuan Yao
Affiliation:
Keywords: stem cells, heterochromatin, non-mammalian reporter genes
Abstract: An obstacle confronting gene therapy in stem cells is transcriptional silencing of the vector. Here, we discuss recent data indicating that oncoretrovirus and lentivirus vectors are silenced by multiple epigenetic pathways that result in DNA methylation and histone modifications. Both vector types can be variegated in stem cells and expression is often extinguished during differentiation. We propose a novel model of retrovirus silencing in which epigenetic pathways compete to recruit histone deacetylases, de novo methyltransferases, histone H1 and MeCP2 to the provirus. These chromatin modifications may act in concert with heterochromatin at or near the integration site to establish silencing or variegation respectively. Retrovirus vector designs for stem cells should delete virus silencer elements, incorporate strong positive regulatory elements and insulators, and avoid non-mammalian reporter genes. In addition, cancer stem cells that continually repopulate a growing tumour may share silencing pathways with normal stem cells. Ultimately, optimized vector designs may prove to be valuable tools for gene therapy of both normal and cancer stem cells.
Export Options
About this article
Cite this article as:
Ellis James and Yao Shuyuan, Retrovirus Silencing and Vector Design: Relevance to Normal and Cancer Stem Cells?, Current Gene Therapy 2005; 5 (4) . https://dx.doi.org/10.2174/1566523054546233
DOI https://dx.doi.org/10.2174/1566523054546233 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modification of Polyfluoro-Containing 3-(Ethoxycarbonyl)flavones by Biogenic Amines and Amino Acids
Current Organic Synthesis New Drugs for Immune Targeting
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) The Chemistry and Pharmacology of Genistein
The Natural Products Journal Peptides for Diagnosis and Treatment of Colorectal Cancer
Current Medicinal Chemistry Diffusion-Weighted Imaging in Abdominal Oncology
Current Medical Imaging The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Microfilament Actin Remodeling as a Potential Target for Cancer Drug Development
Current Cancer Drug Targets Editorial (Thematic Issue: <i>In Silico</i> Drug Design and Medicinal Chemistry)
Current Topics in Medicinal Chemistry Determination of Epsilon Aminocaproic Acid Based on Charge Transfer Complexation with p-Nitrophenlol by Spectrophotometry
Current Pharmaceutical Analysis Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects
Current Bioinformatics New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Ion Exchange Resins Transforming Drug Delivery Systems
Current Drug Delivery Meet Our Editorial Board Member
Current Drug Targets The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions
Current Drug Targets miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential
Current Medicinal Chemistry Toll-Like Receptor (TLR) Response Tolerance: A Key Physiological “ Damage Limitation ” Effect and an Important Potential Opportunity for Therapy
Current Medicinal Chemistry Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy